Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06609174 · ClinicalTrials.gov registry record · NA
AI-SCREENDCM Decentralized Clinical Trial - Pilot Study
A NA study, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 119
- Enrollment target
NCT06609174: Completed NA study, sponsored by Mayo Clinic.
NCT06609174 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 119 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06609174, a NA study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 119 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the feasibility and impact of screening FDR of DCM probands using a mobile ECG with the ability to transmit the ECG for cloud-based AI analysis to detect reduced left ventricular ejection fraction (LVEF). This protocol will examine the impact of incorporating the screening AI enhanced ECG into standard of care recommendations.
Interventions
- DIAGNOSTIC_TEST KardiaRx ECG Screening and AI interpretation of ECG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2024-10-18 |
| Est. Completion | 2025-09-26 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06609174
The ClinicalTrials.gov registry entry for NCT06609174 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which KardiaRx ECG Screening and AI interpretation of ECG is the first listed.
NCT06609174 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06609174 about?
NCT06609174 is a clinical study titled "AI-SCREENDCM Decentralized Clinical Trial - Pilot Study". The purpose of this study is to assess the feasibility and impact of screening FDR of DCM probands using a mobile ECG with the ability to transmit the ECG for cloud-based AI analysis to detect reduced left ventricular ejection fraction (LVEF). This protocol will examine the impact of incorporating t...
What is the current status of trial NCT06609174?
This trial is currently completed. It is a NA study. The enrollment target is 119 participants. The study started on 2024-10-18. Estimated completion is 2025-09-26.
What interventions are being tested in trial NCT06609174?
The interventions under investigation include: KardiaRx ECG Screening and AI interpretation of ECG (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06609174?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.